Regional delivery of angiotensin II and phenylephrine caused significantly greater retention of marker in tumour than liver with an overall 4-fold increased retention of marker one minute after its injection. Ninety minutes after injection there was still significant retention of marker compared to control animals. Regional delivery of hepatic artery vasoconstrictors increase delivery of marker and may increase delivery of chemotherapeutic drug to liver tumour.
The effects of intra-arterial vasoconstrictors on the distribution of a radiolabelled low molecular weight marker in an experimental model Regional delivery of angiotensin II and phenylephrine caused significantly greater retention of marker in tumour than liver with an overall 4-fold increased retention of marker one minute after its injection. Ninety minutes after injection there was still significant retention of marker compared to control animals. Regional delivery of hepatic artery vasoconstrictors increase delivery of marker and may increase delivery of chemotherapeutic drug to liver tumour.
A substantial proportion of patients with colorectal cancer develop hepatic metastases and, in the majority, the liver is the only site of recurrence (Rapoport & Burleson, 1970; Russell et al., 1984; Finlay & McArdle, 1983) . Systemic chemotherapy does not improve survival and is associated with significant undesirable, unpleasant and sometimes fatal side-effects (Kemeny et al., 1980) . In recent years interest has been accumulating in regional chemotherapy for the treatment of hepatic metastases derived from colorectal primaries. The rationale of the treatment is that higher concentration of cytotoxic drugs metabolised by the liver can be infused via the hepatic artery and are retained within the organ minimising the systemic side-effects (Ensminger et al., 1978; Sigurdson et al., 1986) . Furthermore, because the blood supply of overt hepatic metastases is derived principally from the hepatic artery (Ackerman et al., 1969; Taylor et al., 1979) it was postulated that the tumour should retain more of the cytotoxic drug than normal liver cells.
Although regional hepatic artery chemotherapy improves the tumour response rates compared to systemic chemotherapy (Kemeny et al., 1987) , survival is not affected. The disappointing results of regional chemotherapy may be related to the relatively hypovascular nature of the majority of liver metastases (Taylor et al., 1979) which limits presentation of the drug to the tumour. Numerous vasoactive drugs have been used to manipulate hepatic blood flow in tumour bearing patients and animals (Sasaki et al., 1985; Burton & Gray, 1987) . Histological studies have shown that the blood vessels of tumour are undifferentiated, composed only of endothelium, lack muscular or venous elements, and thus would have no adrenergic innvervation (Mattson et al., 1977) . These observations suggest that vasoactive drugs would have a maximal effect on the normal liver vasculature, with little or no effect on the tumour vessels (Mattson et al., 1978) . This hypothesis was supported by observations which demonstrated that angiotensin II, an hepatic arterial vasoconstrictor, increased the tumour:normal tissue blood flow ratio when infused into the hepatic artery (Sasaki et al., 1985) . However (Chan et al., 1984) .
We have developed a model of hypovascular liver tumour in the rat, and a technique using a radiolabelled marker of similar molecular size to cytotoxic drug to determine whether manipulation of intrahepatic blood flow by vasoactive agent increases its delivery and retention by liver tumour relative to normal liver tissue (Cooke & Chang, 1990; Hemingway et al., 1989a We have previously characterised the haemodynamic changes associated with the growth and development of this tumour (Cooke & Chang, 1990; Hemingway et al., 1989b,) . Briefly, overt tumour derives its blood supply almost entirely from the hepatic artery, with a minimal contribution by the portal vein, is relatively hypovascular compared to the surrounding normal liver (tumour:liver blood flow ratio 0.6:1) and exhibits no arteriosystemic shunting. This hepatic tumour therefore displays many of the haemodynamic characteristics of hepatic metastases derived from colorectal primary tumours in man.
Marker distribution
Tumour bearing rats were anaesthetised with sodium pentobarbitone (Sagatal, 30 mg kg-'), and a silastic catheter (Portex, Hythe, UK, outside diameter 0.61 mm) introduced into the gastroduodenal artery. The cannula was positioned so that its tip lay at the junction of the coeliac and hepatic arteries. Under direct vision, using an operating microscope, an injection of normal saline was administered via the cannula to ensure the injectate passed into the hepatic artery and not down the coeliac artery.
A second cannula was introduced into the right femoral artery for continuous measurement of the arterial blood pressure using a strain gauge transduce attached to a Gould pen recorder (Gould Medical Ltd., Lutterworth, UK). The left femoral vein was cannulated for systemic infusion of angiotensin II where necessary.
Controls
Twenty control rats received an intrahepatic arterial bolus of saline via the cannula in the gastroduodenal artery. Thirty seconds later 50 "l of 9'9Tc MDP (100 MBq ml-') was infused via the the hepatic artery under direct vision over 30 s. Ten animals were killed at one, and 10 animals at 90 min after the injection. The tumour was dissected from normal liver tissue, weighed and placed in vials for counting on a well gamma counter (Packard, UK).
Systemic Angiotensin II Angiotensin II (Ciba-Geigy) diluted in normal saline to a concentration of 0.83 gg ml-', was infused through the venous cannula at a rate of 3.6 ,g min-' g x I0-. In ten rats, 90 s after commencing the infusion (i.e., the peak of the blood pressure response) 50 iLl of 9'Tc labelled MDP (100 MBq m-') was injected via the hepatic arterial catheter over 30 s. One minute later the ten animals were killed, tumour was dissected from normal liver tissue, and gamma counted as described above.
Intra-arterial Angiotensin Angiotensin II (Ciba-Geigy) was diluted in normal saline to a concentration of 5 jig ml-'. Fifty 1l (0.25 
A reference sample of MDP was withdrawn from the stock solution immediately after the hepatic artery injections and counted immediately prior to the samples. The counts were corrected for decay of 9'Tc and the results expressed as percentage of the injected dose (% ID) per gram of tissue. Statistical analysis of the distribution of labelled marker between liver and tumour in control and experimental animals was by non-parametric Mann-Whitney test.
Results
Mean hepatic replacement The mean hepatic replacement by tumour was 27.3 ± 15.2% (mean ± s.d.).
Angiotensin II Intravenous infusion
Distribution of marker During systemic administration of angiotensin II the percentage injected dose of regionally delivered MDP per gram of liver at one minute (16.0 ± 5.4 x 10-1 mean ± s.d.) was significantly greater (P<0.02) than in control animals (3.55 ± .15. x 10-1). However the percentage injected dose of MDP per gram for tumour in angiotensin treated rats (9.6 ± 3.0 x 10-1) was not significantly greater than that in control animals (5.17 ± 0.55 x 10-1) (Figure 1 ). The tumour:liver ratio in rats infused with angiotensin II was 0.6:1 compared to 1.5:1 in controls.
Blood pressure Arterial blood pressure rose from 117.8 ± 14.8 mmHg to 149 ± 22.4 mmHg after IV infusion of angiotensin II. The time from the commencement of the angiotensin II infusion to the first change in blood pressure was 8.14 ± 7.58 s and the maximal effect was observed at 29.0 ± 19.8 s. In four of the rats, the peak blood pressure was maintained until the animals were killed one minute after the MDP injection. One minute The percentage of the injected dose of MDP per gram of normal liver tissue in angiotensin II treated rats (11.1 ± 1.1 x 10-1) was significantly greater (P<0.02) than in control animals (3.55 ± 0.15 x 10-1). Similarly the percentage injected dose of marker per gram in tumour tissue (23.1 ± 5.7 x 10-1) was significantly greater in angiotensin II treated animals (P<0.01) than that in controls (5.17 ± 0.55 x 10-1) (Figure 2 ). The tumour:liver ratio .at one minute in angiotensin II treated rats was 2.1:1.
90 minutes Ninety minutes after the intra-arterial injection of MDP and angiotensin II there was still significant retention (P<0.01) of MDP both in normal liver (6.4± 1.4 x 10-1) and in tumour (3.1 ± 1.07 x 10-1) compared to controls normal liver (0.79 ± 0.07 ± 10-1) and tumour (0.61 ± 0.04 x 10-1) (Figure 3 ). 90 minutes Ninety minutes after the bolus injection of MDP there was still significant retention of marker compared to controls both in tumur (6.9 ± 2.6 x 10-1; controls 0.61 ± 0.04 x 10-1) and in normal liver (5.9 + 0.11; controls 0.79 ± 0.07 x 10-1; P <0.01) ( Figure 5 ).
Arterial blood pressure The mean arterial blood pressure rose from 88 ± 7.4 mmHg (mean ± s.d.) to 135 ± 8.3 mmHg after phenylephrine injection. The time to the first change in blood pressure was 7.83 ± 3.37 s (mean ± s.d.) and the time to maximal response was 14.1±6.48s.
Discussion
The prognosis for patients with liver metastases derived from colorectal carcinoma remains poor. Resection of the metastases is rarely feasible and systemic chemotherapy does not in general prolong survival (Hughes et al., 1986; Kemeny et al., 1980) , although recent studies of systemic 5-FU and leucovorin have shown a minor survival benefit (Kerr, 1989) . Similarly, although regional chemotherapy has produced objective tumour responses in up to 50% of patients it has not be demonstrated to significantly improve survival (Kemeny et al., 1987) . A possible explanation of the failure of regional chemotherapy to improve survival in these patients is that there is no preferential delivery of the cytotoxic drug to the tumour (Sigurdson, 1986 ) since many are relatively hypovascular compared to the surrounding liver parenchyma. The study by Daly et al. which demonstrated improved response rates to regional chemotherapy in patients with hypervascular metastases compared to patients with hypovascular metastases (Daly, 1985) and which reported improved FUDr uptake in metastases which had a high uptake of MAA would appear to support this hypothesis (Daly et al., 1985) .
Sasaki infused 8'm Krypton into the hepatic artery of patients with liver tumours and estimated arterial flow to liver and tumour from the detected radioactivity in both tissues (Sasaki et al., 1985) . They demonstrated that the ratio of tumour to liver blood flow increased to 3.3:1 after an intra-arterial infusion of angiotensin II. The preferential supply of blood to tumour observed in their study is similar to the results of this study in which angiotensin II and phenylephrine enhanced the retention of an inert marker resembling chemotherapeutic drug by hepatic tumour. Intraarterial administration of angiotensin II resulted in a significant retention of marker in both normal liver tissue and tumour. One minute after administration the retention of the marker was increased 4-fold within the tumour compared to control animals. Since the retention of marker in tumour was greater than that of normal liver there was also an increase in the tumour: liver ratio to 2.1:1 in experimental animals. Phenylephrine which is also an hepatic arterial vasoconstrictor produced similar results to angiotensin II. One minute after administration of the phenylephrine both tumour and liver retention of marker were increased with a tumour: liver ratio of 2.1: 1. The experiments with both agents indicate that regionally delivered vasoconstrictors increase delivery of a marker to liver tumour. The findings of this investigation are similar to our previously reported results with degradable starch microspheres (Cooke & Chang, 1990) . Concomitant administration of degradable starch microspheres and marker produced significant retention of marker in both liver and tumour. In this study, 1 min after administration of DSM the tumour: liver ratio was 2.3:1. Angiotensin II, phenylephrine and DSM would therefore appear to effect an intrahepatic redistribution of blood, diverting blood flow and marker towards liver tumour.
Our results are also in agreement with those of Sasaki using intravenous infusions of angiotensin II to manipulate tumour blood flow. Intravenous angiotensin II did not consistently improve the tumour:liver blood flow ratio and was less than 1:1 for the first 2 min of his experiments. The findings are similar to those of this study in which the concentration of marker was greater than in tumour after IV angiotensin II, with a tumour:liver ratio of 0.6:1.
The effects of angiotensin II on systemic and hepatic haemodynamics are transient and of short duration, and the administration of this vasoactive agent is occasionally followed by a rebound hypotension. The maximum change in liver blood flow occurs before the maximum change in blood pressure and the regionally delivered marker must be given during the period when there is maximum alteration in liver blood flow. Ninety minutes after a single IA bolus injection of phenylephrine or angiotensin, although systemic haemodynamics had returned to the baseline values, the retention of marker in both liver and tumour was significantly greater than in control animals. In the control animals, however, the marker was rapidly washed out of both the normal liver and tumour by the hepatic arterial and portal venous flows resulting in minimal retention at 90 min.
This study contrasts with our previously reported findings using DSM where almost all the marker was washed out of the normal liver at 90 min, presumably by restoration of portal venous flow after degradation of the microspheres. It suggests that the effects of arterial vasoconstrictors on the intrahepatic vasculature persist for longer periods than the effects on systemic blood pressure which are transient and only last for approximately 3 min after the injection. Alternatively, the marker may be already outside the vascular space, either in the interstitial tissues or within the cells which results in a reduction of marker wash out. However, this explanation seems unlikely since the marker is washed out of both normal liver tissue and tumour control animals.
The results of this study suggest that hepatic arterial vasoconstrictors can improve drug delivery to liver tumour, especially hypovascular tumours and may improve the results of regional chemotherapy.
